Our work revealed that the abnormal expression of FBXL16 in Ishikawa cells led to the inhibition of GSK3β-dependent cyclin D1 degradation and ultimately the promotion of MPA resistance in endometrial carcinoma. This evidence concerns the gene GSK3B and endometrial carcinoma.